Abstract

Osteoarthritis (OA) is a debilitating inflammation related disease characterized by joint pain and effusion, loss of mobility, and deformity that may result in functional joint failure and significant impact on quality of life. Once thought of as a simple “wear and tear” disease, it is now widely recognized that OA has a considerable metabolic component and is related to chronic inflammation. Defects associated with primary cilia have been shown to be cause OA-like changes in Bardet–Biedl mice. We examined the role of dysfunctional primary cilia in OA in mice through the regulation of the previously identified degradative and pro-inflammatory molecular pathways common to OA. We observed an increase in the presence of pro-inflammatory markers TGFβ-1 and HTRA1 as well as cartilage destructive protease MMP-13 but a decrease in DDR-2. We observed a morphological difference in cartilage thickness in Bbs1M390R/M390R mice compared to wild type (WT). We did not observe any difference in OARSI or Mankin scores between WT and Bbs1M390R/M390R mice. Primary cilia appear to be involved in the upregulation of biomarkers, including pro-inflammatory markers common to OA.

Highlights

  • Osteoarthritis (OA) is a debilitating disease characterized by joint pain and effusion, loss of mobility, and deformity that may result in functional joint failure and significant impact on quality of life (1–3)

  • We observed primary cilia in zebrafish chondrocytes residing in the mandible (Figure 1A) indicated in green staining

  • In a histological comparison of 18-week-old wild type (WT) and Bbs1M390R/M390R mutant knee joints stained with SafraninO, Fast Green we observed thicker cartilage (p < 0.01) in

Read more

Summary

Introduction

Osteoarthritis (OA) is a debilitating disease characterized by joint pain and effusion, loss of mobility, and deformity that may result in functional joint failure and significant impact on quality of life (1–3). It is one of the most common chronic diseases in the United States, with recent estimates suggesting that more than 27 million adults suffer from clinical OA in this country. As upward obesity trends continue it is probable that an increase in clinical OA will be observed (1–3). There is currently no cure, and treatment options are minimal, with pain management and surgical joint replacement procedures being the only reprieve.

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.